In CYP2C19*2/*2 carriers, elevated plasma levels (69 mg/L) of PHT have been observed, leading to neurotoxicity (manifested as dizziness, nystagmus, ataxia, and excessive sedation) [34]. Here, CYP2C19 is linked to pulmonary hypertension, primary, 1.